Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
You may also be interested in...
Acorda Buys Its Way Into A Parkinson's Franchise
Having acquired Parkinson's candidate CVT-301 in the 2014 purchase of Civitas, Acorda sees Biotie's Phase III tozadenant as an ideal candidate to create a complementary Parkinson's disease franchise.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.